Finance

InVivo Therapeutics Announces Pricing of $13.2 Million Underwritten Public Offering

June 22, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of an underwritten public offering of 388,403 shares of its common stock, together with warrants to purchase 388,403 shares of common stock at a combined price to the public of $2.00 per share and warrant, as well as pre-funded warrants to purchase up to […]

Autolus Announces Pricing of Initial Public Offering

June 22, 2018

LONDON – 22 June, 2018 – Autolus Therapeutics plc (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares (“ADSs”) representing 8,823,530 ordinary shares at an initial public offering price of $17.00 per ADS for total […]

Oncobiologics Announces Conversion of Majority of Series A Convertible Preferred Stock

June 21, 2018

CRANBURY, N.J., June 20, 2018 (GLOBE NEWSWIRE) — Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced that GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s strategic business partner and largest investor, has converted 80% of its Series A convertible preferred stock (Series A) into common stock (or 208,836 shares of Series A into 31,572,617 shares […]

Deciphera Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 21, 2018

WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that the underwriters of its previously announced underwritten public offering, which closed on June 11, 2018, have exercised in full their option to purchase an additional 645,000 shares of Deciphera’s common stock. Including this […]

Magenta Therapeutics Announces Pricing of Initial Public Offering

June 21, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced the pricing of its initial public offering of 6,666,667 shares of its common stock at a price to the public of $15.00 per share, for total gross proceeds of […]

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

June 21, 2018

BOSTON, June 20, 2018 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the pricing of its public offering of 5,732,000 shares of its common stock at a public offering price of $26.42 per share. […]

Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market

June 21, 2018

HOUSTON, June 21, 2018 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (NASDAQ:MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that […]

Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Congenital Hyperinsulinism and Acromegaly

June 21, 2018

SAN DIEGO, June 21, 2018 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it has been awarded up to approximately $3.2 million in Small Business Innovation Research (SBIR) grants from the National […]

Cerebral Therapeutics Raises Series A Financing to Advance Clinical-Stage Drug-Device Combination Therapy for Adult Refractory Epilepsy

June 20, 2018

AURORA, Colo., June 20, 2018 /PRNewswire/ — Cerebral Therapeutics, Inc., a clinical-stage company focused on implanted drug-device combination therapies to improve the lives of patients with uncontrolled neurological diseases, announced today the closing of a $3 million Series A financing by institutional investors Granite Point Capital Management, L.P., and Vivo Capital, LLC. Cerebral Therapeutics is […]

iTeos Therapeutics Completes $75 Million Series B Financing

June 20, 2018

Gosselies, Belgium – June 20, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the completion of an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, with participation from additional new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All existing investors also participated in […]

ObsEva Announces Pricing of Follow-on Public Offering

June 20, 2018

Geneva, Switzerland and Boston, MA – June 20, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, announced today the pricing of an underwritten public offering of 4,750,000 common shares at a price of […]

Catabasis Pharmaceuticals Announces Pricing of $42 Million Underwritten Public Offering

June 20, 2018

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten offering of an aggregate of 42,000,000 units. Each unit is comprised of one share of common stock and one common warrant to purchase one share of common stock, at a price […]

AcuraStem Receives Fast-Track SBIR Grant for the Development of a Novel Small Molecule Therapy to Treat ALS

June 19, 2018

MONROVIA, Calif.–(BUSINESS WIRE)–AcuraStem a fast-growing, innovative biotech company in Monrovia, California, has been awarded a 3.7 million dollar Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, “AS2015”, focused on treating patients with the genetic […]

Karuna Receives $8 Million Wellcome Trust Award to Advance First-in-Class Phase 2 Clinical Program in Schizophrenia

June 19, 2018

BOSTON–(BUSINESS WIRE)–Karuna Pharmaceuticals, an affiliate of PureTech Health plc (LSE: PRTC), focused on targeting muscarinic receptors for the treatment of disorders marked by psychosis and cognitive symptoms, today announced that it has been awarded approximately $8 million by the Wellcome Trust. The funding will be used to further advance clinical development of Karuna’s lead program, […]

NantKwest Names Sonja Nelson Chief Financial Officer

June 19, 2018

CULVER CITY, Calif.–(BUSINESS WIRE)–NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson, chief accounting officer for the company, to the role of Chief Financial Officer (CFO). “I’m excited to have her elevated to this leadership role and look forward to working closely with her.” Tweet this Nelson, who first joined NantKwest in 2015, […]

Decibel Therapeutics Closes $55 Million Series C Financing

June 19, 2018

BOSTON–(BUSINESS WIRE)–Decibel Therapeutics, a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, today announced that it has raised $55M in a Series C financing. All existing investors, including Third Rock Ventures, GV, SR One, and Regeneron Pharmaceuticals, participated in the round, and were joined by new […]

Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million

June 19, 2018

NEW HAVEN, Conn. and NEW YORK, June 18, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) and Royalty Pharma announced today that Biohaven has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds thereof to Royalty Pharma […]

Translate Bio Launches Proposed Initial Public Offering

June 18, 2018

LEXINGTON, Mass.–(BUSINESS WIRE)–Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has launched an initial public offering of 7,700,000 shares of its common stock. In addition, Translate Bio expects to grant the underwriters a […]

Record growth at Sterling Pharma Solutions

June 18, 2018

A UK-based contract development and manufacturing organisation (CDMO) has more than doubled its sales since its formation in 2016 as demand for its hazardous chemistry capabilities and active pharmaceutical ingredient (API) services grows. Sterling Pharma Solutions, which launched as an independent CDMO following a management buyout (MBO) of the Shasun Pharma Solutions Dudley site in […]

Therapeutic Solutions International Announces the Appointment of James Veltmeyer, MD as Chief Medical Officer

June 18, 2018

OCEANSIDE, Calif., June 18, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire — Therapeutics Solutions International, Inc., (OTC Markets:TSOI) previously announced their plans to provide access to its clinical stage cancer immunotherapy product StemVacs under the Right To Try law signed by President Trump on May 30th 2018, and have appointed Dr. James Veltmeyer as […]

Verastem Oncology Announces $43.0 Million Offering of Common Stock

June 15, 2018

BOSTON–(BUSINESS WIRE)–Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced a registered sale to funds managed by Consonance Capital of 7,166,666 shares of the Company’s common stock at a price of $6.00 per share. […]

Bristol-Myers Squibb Announces Dividend

June 15, 2018

NEW YORK–(BUSINESS WIRE)–The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.40) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on August 1, 2018, to stockholders of record at the close of business on July 6, […]

Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility

June 15, 2018

IRVING, Texas, June 14, 2018 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq:RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that it entered into an amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, which increased the Company’s term loan facility from $45 million to $125 million. […]

Verrica Pharmaceuticals Inc. Announces Pricing of Initial Public Offering

June 15, 2018

WEST CHESTER, Pa., June 14, 2018 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public […]

Compugen Announces $21 Million Registered Direct Offering of Ordinary Shares and Warrants

June 15, 2018

HOLON, Israel, June 15, 2018 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN)(CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors providing for the issuance of approximately 5.3 million of its ordinary shares at a purchase price […]

Achema 2018: Lifetime Efficiency – new comprehensive concept exploits untapped potentials for users in the production of solid formulations

June 14, 2018

Fette Compacting has developed a new service offering for the optimization of tablet production and capsule filling under the name Lifetime Efficiency. This service is based on the comprehensive analysis and systematic improvement of all production processes. It enables users not only to exploit previously untapped potentials, but also to increase the efficiency of production […]

Sanofi and Recipharm announce transfer of Holmes Chapel Manufacturing site

June 14, 2018

Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm. “Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel respiratory products. As an already successful CMO […]

IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock

June 13, 2018

DANBURY, Conn., & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 12,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, […]

Synergy Pharmaceuticals Announces Amendment to CRG Debt Agreement

June 13, 2018

NEW YORK–(BUSINESS WIRE)–Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has received a waiver to extend the draw down date of the second borrowing under its Term Loan Agreement with CRG LP from June 30, 2018 to August 29, 2018. […]

MeiraGTx Announces Closing of Initial Public Offering

June 13, 2018

LONDON and NEW YORK, June 12, 2018 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the closing of its initial public offering of 5,000,000 ordinary shares at a public offering price of $15.00 per share. The gross proceeds to MeiraGTx, before underwriting discounts and commissions, are […]

FEEDBACK